5 Things We Now Know About Multiple Myeloma

Rates of this blood cancer have jumped more than 125% worldwide since the 1990s. But there's reason to have hope: Today, life expectancy has at least doubled in some cases. That's thanks to increased research, new learnings and innovative advances and Johnson & Johnson is at the forefront of this crucial work.

her that she had it.

By Barbara Brody, November 08, 2022

She recalls telling others about her diagnosis and having to correct them when they misunderstood and

thought she had melanoma, a form of skin cancer, rather than myeloma, a type of blood cancer. Prior to her diagnosis, Chmielewski spent two years seeing an orthopedic surgeon for severe back pain. The doctor insisted that she had degenerative disc

disease, a common cause of back pain. But that wasn't what was wrong with Chmielewski, and pain medication and physical therapy weren't helping. Finally, the pain got so severe that she went back to the doctor in tears. "I was a 5th grade teacher at the time, yet I couldn't stand up long enough to be the playground monitor. I couldn't take kids on field trips because the bumpy bus ride would be too painful," she says.

including what advances may lie on the horizon.

until the disease is advanced.

The doctor finally sent her for X-rays, which revealed numerous compression fractures in her back. Chmielewski was getting ready to undergo surgery to stabilize her spine when preop blood work came back "totally abnormal." She was quickly referred to a hematologist, who diagnosed her with multiple myeloma.

herself, as well as the public, about the disease. She's become an outspoken patient advocate who posts extensively on Twitter, speaks at medical conferences and shares her experience with pharmaceutical companies that are seeking patient input, including the Janssen Pharmaceutical Companies of Johnson & Johnson.


Multiple myeloma may not cause any noticeable symptoms

the fact that the cancer often grows in multiple areas of the marrow.) In healthy people, plasma cells make antibodies to multiple targets, protecting patients against all types of infections. In patients with multiple myeloma, however, plasma cells

Multiple myeloma typically starts in the bone marrow, which is the birthplace of new blood

cells and specifically is impacted by antibody-producing white blood cells known as plasma

grow abnormally in an uncontrolled fashion, rendering the cells cancerous. As these harmful cells build up in the bone marrow and often make an abnormal antibody called an M protein, there's less room for healthy blood cells to grow. The result? A potential lack of adequate red blood cells, platelets and other types of white blood cells needed to successfully fight off infections.



The disease is relatively rare, but it's becoming more common. Nearly 35,000 adults in the U.S. are diagnosed with myeloma each year. That makes it a relatively rare cancer compared to breast cancer (about 264,000 When I was newly cases each year) or lung cancer (about 240,000 per

Of course, not everyone who gets the disease fits the mold: Chmielewski, a white woman, was diagnosed in her 40s.

year), but it's hardly an insignificant number. Also

noteworthy is the fact that myeloma is on the rise.

and 2016.

Worldwide, incidence jumped 126% between 1990

This trend might be explained by the fact that people

increases with age and is most often diagnosed in

people over age 60. It's also more prevalent in Black

people than it is in white people, and it's slightly more

are living longer, because the risk of myeloma

common in men than it is in women.

require treatment.

Schecter.

stages aren't accompanied by symptoms.

The other precursor state, called smoldering multiple

an asymptomatic form of myeloma that doesn't meet

the CRAB criteria, and the standard of care is to *not*

smoldering multiple myeloma will progress to multiple

treat those patients but rather just closely monitor

them." However, about 15% of people with

regimens are often adjusted.

of medications administered both orally and

to induce remission. The current mainstays of

cells and also harness the power of the body's

This induction therapy is often followed by an

the patient's own bone marrow stem cells are

bind to a protein on myeloma cells.

Because multiple myeloma is a blood cancer rather

Instead, patients receive induction therapy comprised

subcutaneously (under the skin), which are designed

treatment come from three main classes of drugs,

explains Dr. Schecter: IMiDs, or immunomodulatory

drugs, which have direct activity against the plasma

immune system; proteasome inhibitors, which can

help kill myeloma cells; and CD38 antibodies, which

autologous stem cell transplant—a procedure in which

removed from the blood and infused after a high dose

cells in the bone marrow. However, many patients are

progresses despite a transplant, oncologists generally

of chemotherapy is used to kill off cancerous stem

too old or frail to undergo a stem cell transplant.

When stem cell transplants fail or the disease

trial, she says.

than a solid tumor, it's rarely treated with surgery.

myeloma within three years.

myeloma, is more of a middle ground, he explains. "It's

CRAB criteria. But because the disease may be preceded by two precursor states, others The earlier precursor state is MGUS, which stands for Monoclonal Gammopathy of Undetermined Significance. Only 1% of people with MGUS progress to multiple myeloma.

For that reason, scientists are working to identify who is at highest risk of progressing. Clinical trials designed to find out which smoldering multiple

myeloma patients may benefit from earlier treatment are currently underway. "The standard of care is evolving," says Dr. Schecter.

Multiple myeloma is rarely treated with surgery, and drug

"Most of them can be closely monitored and will hopefully never need treatment," says Dr.

first diagnosed, there were only a few myeloma drugs on the market ... Now, when someone relapses, there are multiple combinations of approved drugs that patients could try, some of which Janssen

has developed.

When Chmielewski was

There's no cure for the large majority of patients, but people now have more treatment options—and hope. When Chmielewski was first diagnosed, there were only a few myeloma drugs on the market. Fortunately, these treatments did put her into long-term remission. "If those had stopped working for me, there would have been nothing else available" outside of a clinical Now, when someone relapses, there are multiple combinations of approved drugs that patients could try, some of which Janssen has developed, says Blake Bartlett, Ph.D., head

incorporate newer options, including some of the latest immunotherapies, may now expect to live more than five or six years with the disease, he adds.

I don't have to worry as much if I relapse someday." As research in this area continues to advance, so does hope. A potential cure might even be on the horizon, perhaps by treating patients earlier with different combinations or sequences of existing or developing therapies that are being investigated in clinical trials.

"We're focused on developing first-in-class or best-in class therapies and really aim to


change the treatment landscape," says Bartlett. "We're also conducting clinical studies to

determine the best way to integrate our new generation of therapies into the standard of

care, which might someday help us deliver cures for most patients."


around to see her get married." She is still faring well on older drugs she's been taking for

many years, but knowing that other options are out there "gives me so much hope, because



of Multiple Myeloma & Plasma Cell Disorders, Global Medical Affairs, Janssen. The current options include drugs with a variety of mechanisms of action in at least five separate drug classes. As myeloma treatments are advancing, people have more hope in managing the disease. "About 20 years ago, the life expectancy was about three years, and overall now it is at least five to six years," says Bartlett. Although long-term data on the latest therapies and updated drug regimens is not yet available, patients with standard risk features who

"My daughter was 19 when I was diagnosed, and now we're going dress shopping for her wedding next year," says Chmielewski. "When I was newly diagnosed, I never thought I'd be



A close-up view of antibodies

for her wedding next year. Cindy Chmielewski, Patient Advocate

diagnosed, I never thought I'd be around to see my daughter get married. Now we're going dress shopping

In the 14 years since, Chmielewski, now in remission, has made it her mission to educate Johnson & Johnson has been dedicated to developing innovative treatments for multiple myeloma for nearly 20 years and is committed to working toward its goal of one day eliminating the disease. Here are five things we now understand about this cancer,

Cindy Chmielewski had never heard of multiple myeloma until the day her doctor informed

cells. ("Multiple myeloma" and "myeloma" can be used interchangeably; "multiple" refers to

It's possible to have a precursor condition that might not Some people, like Chmielewski, are diagnosed with full-blown myeloma that meets the may learn at an earlier stage—usually through routine bloodwork, since these precursor